JP2005520780A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520780A5
JP2005520780A5 JP2003511771A JP2003511771A JP2005520780A5 JP 2005520780 A5 JP2005520780 A5 JP 2005520780A5 JP 2003511771 A JP2003511771 A JP 2003511771A JP 2003511771 A JP2003511771 A JP 2003511771A JP 2005520780 A5 JP2005520780 A5 JP 2005520780A5
Authority
JP
Japan
Prior art keywords
threo
formulation
preparation according
treatment
oncological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003511771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520780A (ja
Filing date
Publication date
Priority claimed from US09/903,803 external-priority patent/US6486177B2/en
Application filed filed Critical
Publication of JP2005520780A publication Critical patent/JP2005520780A/ja
Publication of JP2005520780A5 publication Critical patent/JP2005520780A5/ja
Pending legal-status Critical Current

Links

JP2003511771A 2001-07-12 2002-07-11 Ｄ−ｔｈｒｅｏメチルフェニデートを用いる認識および閉経期の障害の治療方法 Pending JP2005520780A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/903,803 US6486177B2 (en) 1995-12-04 2001-07-12 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
PCT/US2002/022039 WO2003005962A2 (en) 2001-07-12 2002-07-11 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate

Publications (2)

Publication Number Publication Date
JP2005520780A JP2005520780A (ja) 2005-07-14
JP2005520780A5 true JP2005520780A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=25418099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003511771A Pending JP2005520780A (ja) 2001-07-12 2002-07-11 Ｄ−ｔｈｒｅｏメチルフェニデートを用いる認識および閉経期の障害の治療方法

Country Status (10)

Country Link
US (7) US6486177B2 (cg-RX-API-DMAC7.html)
EP (1) EP1411943A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005520780A (cg-RX-API-DMAC7.html)
KR (1) KR20040029360A (cg-RX-API-DMAC7.html)
AU (1) AU2002318302B2 (cg-RX-API-DMAC7.html)
CA (1) CA2453510C (cg-RX-API-DMAC7.html)
IL (1) IL159313A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000249A (cg-RX-API-DMAC7.html)
NZ (2) NZ565754A (cg-RX-API-DMAC7.html)
WO (1) WO2003005962A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA98000395A (es) 1995-07-14 2005-04-29 Medeva Europ Ltd Composicion que comprende d-treo-metilfenidato y otra droga.
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
CA2412362A1 (en) * 2000-06-20 2001-12-27 Arthur L. Heerbst Cox-2 inhibitors and the prevention of the side effects of radiation therapy
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
JP4959335B2 (ja) * 2003-10-08 2012-06-20 マリンクロッド エルエルシー メチルフェニデート溶液および関連する投与および製造方法
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
JP2008507552A (ja) * 2004-07-22 2008-03-13 ワイス 神経系障害および状態の治療方法
JP2008507550A (ja) * 2004-07-22 2008-03-13 ワイス 神経系障害及び状態の処置方法
US20060100243A1 (en) * 2004-10-22 2006-05-11 Mark Froimowitz Methylphenidate analogs and methods of use thereof
EP1830648A4 (en) * 2004-12-09 2008-03-12 Celgene Corp TREATMENT WITH D-THREO-METHYLPHENIDATE
CA2595400C (en) 2005-01-20 2017-01-17 Institute For Molecular Medicine, Inc. Methylphenidate derivatives and their use in the treatment of angiogenic diseases and conditions
JP5274844B2 (ja) * 2005-01-20 2013-08-28 インスティチュート フォー モレキュラー メディスン インコーポレイテッド メチルフェニデート誘導体を含む治療剤
EP1904059A2 (en) * 2005-07-21 2008-04-02 Wyeth a Corporation of the State of Delaware Method for treating nervous system disorders and conditions
KR101495146B1 (ko) 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
US9345558B2 (en) 2010-09-03 2016-05-24 Ormco Corporation Self-ligating orthodontic bracket and method of making same
EP2616055A1 (en) * 2010-09-13 2013-07-24 Tenera Therapeutics, LLC Compositions for treating cancer treatment - related fatigue
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
DK2755498T3 (en) * 2011-09-15 2018-05-22 Friulchem Spa COMPOSITION FOR ORAL ADMINISTRATION FOR ANIMALS AND PROCEDURE FOR OBTAINING
KR101312286B1 (ko) * 2012-11-26 2013-09-27 (주)비씨월드제약 즉시방출 및 조절방출 특성을 갖고 d-트레오-메틸페니데이트를 포함하는 약학 조성물
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US49205A (en) * 1865-08-01 Improvement in machines for hulling grain
US32335A (en) * 1861-05-14 Island
US19535A (en) * 1858-03-02 Improvement in sewing-machines
US105134A (en) * 1870-07-05 Thomas sheehan
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
GB589625A (en) 1944-01-19 1947-06-25 Chem Ind Basel Manufacture of new pyridine and piperidine compounds
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
GB788226A (en) 1953-12-23 1957-12-23 Ciba Ltd Stereoisomers of ª‡-phenyl-ª‡-piperidyl-(2)-acetic acid and process of making same
GB878167A (en) 1958-11-17 1961-09-27 Ciba Ltd New acetic acid esters
SU466229A1 (ru) 1973-01-23 1975-04-05 Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты
US4137300A (en) 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
US4410700A (en) * 1980-07-03 1983-10-18 The United States Of America As Represented By The Department Of Health And Human Services Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution
DE3279999D1 (en) * 1981-09-30 1989-11-30 Nat Res Dev Compositions comprising encapsulated particles
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4986987A (en) * 1986-05-09 1991-01-22 Alza Corporation Pulsed drug delivery
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5283193A (en) 1988-06-27 1994-02-01 Asahi Kasei Kogyo K.K. Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5284769A (en) 1989-10-16 1994-02-08 Chiros Ltd. Process for preparing a single enantiomer of a lactam using lactamase
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
DE69229881T2 (de) * 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical Industries, Ltd. Tablette mit verzögerter freisetzung
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5331000A (en) 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5299121A (en) * 1992-06-04 1994-03-29 Medscreen, Inc. Non-prescription drug medication screening system
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
CA2141572C (en) 1992-08-03 2001-02-06 James W. Young Terfenadine metabolites and their optically pure isomers for treating allergic disorders
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3091618B2 (ja) 1993-01-29 2000-09-25 四郎 小林 開環重合法および開環重合用酵素触媒
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
MXPA98000395A (es) 1995-07-14 2005-04-29 Medeva Europ Ltd Composicion que comprende d-treo-metilfenidato y otra droga.
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
JPH11509227A (ja) 1995-07-14 1999-08-17 カイロサイエンス・リミテッド ｄ−トレオ−メチルフェニデートの治療的使用
US5733756A (en) 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
MX9805870A (cg-RX-API-DMAC7.html) 1996-01-22 1999-01-31
US6242464B1 (en) 1996-01-22 2001-06-05 Chiroscience Limited Single isomer methylphenidate and resolution process
JP2000504008A (ja) 1996-02-02 2000-04-04 メデバ・ユアラプ・リミテッド Ｄ―トレオ―（ｒ，ｒ）―メチルフェニデートの調製およびエピメリゼーションによる不要エナンチオマーリサイクルの方法
GB9604943D0 (en) * 1996-03-08 1996-05-08 Chiroscience Ltd Resolution
DE69710051T2 (de) 1996-03-08 2002-08-14 Medeva Europe Ltd., Slough Auflösungsverfahren von threo-methylphenidate
GB9606417D0 (en) 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
ES2264173T3 (es) 1996-11-25 2006-12-16 Alza Corporation Forma de dosificacion para suministrar una dosis creciente.
CZ206299A3 (cs) 1996-12-13 1999-09-15 Medeva Europe Limited Způsob přípravy enantiomerně obohaceného THREO-metalfenidátu
GB9700912D0 (en) 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US5965734A (en) * 1997-01-31 1999-10-12 Celgene Corporation Processes and intermediates for preparing 2-substituted piperidine stereoisomers
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US5936091A (en) * 1997-05-22 1999-08-10 Celgene Corporation Processes and intermediates for resolving piperidyl acetamide stereoisomers
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6395752B1 (en) 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
US6127385A (en) 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
GB9913458D0 (en) 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
WO2001043730A2 (en) 1999-12-17 2001-06-21 Medeva Europe Limited The treatment of convulsive states
US6221883B1 (en) 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
US20020132793A1 (en) * 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US6359139B1 (en) * 2000-11-07 2002-03-19 Celgene Corporation Methods for production of piperidyl acetamide stereoisomers

Similar Documents

Publication Publication Date Title
JP2005520780A5 (cg-RX-API-DMAC7.html)
CA2883751C (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
CN1296040C (zh) 药物组合物
JP2015528471A5 (cg-RX-API-DMAC7.html)
JP2019059760A5 (cg-RX-API-DMAC7.html)
DE14163637T1 (de) Transdermales therapeutisches System, Rivastigmin enthaltend
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
IL189546A0 (en) Therapy for the treatment of disease
CA2453510A1 (en) Treatment of fatigue and cognitive side effects associated with cancer, cancer treatments and menopause with d-threo-methyphenidate
BR122016020433A2 (pt) combinação farmacêutica e uso de um nspacha e de um achei e, opcionalmente, de um naaea
IL315023A (en) Neuroactive steroids for treatment of cns-related disorders
TW200412943A (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CA3119909A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
RU2009131745A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
CA2985305C (en) Combinations of opioids and n-acylethanolamines
PL190733B1 (pl) Zastosowanie przeciwmigrenowej kombinacji i kompozycja farmaceutyczna do leczenia migreny
CN106562966A (zh) 化合物在抗创伤后应激障碍中的用途
JP6116678B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびＮＳＡＲを含む医薬組成物
JP6116672B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗うつ薬を含む医薬組成物
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
US20220169508A1 (en) Pharmaceutical formulations of nitrite and uses thereof
KR20060127136A (ko) 콜린에스테라아제 억제제의 혈관성 우울증을 치료하기 위한용도
CA2480275A1 (en) Statin therapy for enhancing cognitive maintenance
Davis et al. Erythromelalgia